ImmunoBiochem Corporation

4 articles about ImmunoBiochem Corporation

• ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates

  7/24/2023

  ImmunoGen, Inc. announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel biological therapeutics.

• ImmunoBiochem Announces Multi-Target License and Option Agreement with ImmunoGen to Develop Next-Generation Antibody-Drug Conjugates

  7/24/2023

  ImmunoBiochem Corporation announced a multi-target license and option agreement with ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates, to advance novel, first-in-class ADCs.

• Advanced Proteome Therapeutics and ImmunoBiochem Corporation Enter Into a Collaboration and Option Agreement

  2/7/2018

  The companies will evaluate the prospect of combining ImmunoBiochem’s proprietary antibody and APC’s site-selective conjugation technology to produce ADCs with superior properties, targeting triple-negative breast cancer.

• ImmunoBiochem Corporation Partners With The Centre For The Commercialization Of Antibodies And Biologics At The University of Toronto To Advance New Antibody Drug Conjugates

  4/18/2016